A New Frontier in Clinical Trials: The Promise of Synthetic Control Arms

14 Pages

This white paper discusses the concept and potential benefits of Synthetic Control Arms (SCAs) in clinical trials. SCAs, also known as virtual or digital control arms, are created using computational modeling and real-world patient data to simulate a control group. This approach is especially valuable when traditional control arms are not feasible or ethical, such as in rare diseases. SCAs offer numerous advantages, including reducing patient enrollment, costs, and trial timelines while increasing efficiency.

Join for free to read

White Paper Synthetic Control Arm in Clinical Trials

White Paper Leveraging Synthetic Control Arms in Clinical Trials and RWE…

White Paper ONCOLOGY- Making the Asia-Pacific Region a Destination of Choice…

White Paper An interpretable data augmentation framework for improving…

More from Premier Research

White Paper ONCOLOGY- Making the Asia-Pacific Region a Destination of Choice…

White Paper The Path to Acceleration: In Silico Modeling Launches New Wave…

White Paper Transformative Advances in Cancer Immunotherapy: Progress and…

White Paper DIAGNOSTICS- Ten Tips for Establishing the Clinical Utility of…

White Paper

A New Frontier in Clinical Trials: The Promise of Synthetic Control Arms

A New Frontier in Clinical Trials: The Promise of Synthetic Control Arms

You Might Also Like

More from Premier Research